263 related articles for article (PubMed ID: 27122193)
1. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
Brooun A; Gajiwala KS; Deng YL; Liu W; Bolaños B; Bingham P; He YA; Diehl W; Grable N; Kung PP; Sutton S; Maegley KA; Yu X; Stewart AE
Nat Commun; 2016 Apr; 7():11384. PubMed ID: 27122193
[TBL] [Abstract][Full Text] [Related]
2. Structure of the PRC2 complex and application to drug discovery.
Shi Y; Wang XX; Zhuang YW; Jiang Y; Melcher K; Xu HE
Acta Pharmacol Sin; 2017 Jul; 38(7):963-976. PubMed ID: 28414199
[TBL] [Abstract][Full Text] [Related]
3. Polycomb Repressive Complex 2 in Oncology.
Guo Y; Yu Y; Wang GG
Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
[TBL] [Abstract][Full Text] [Related]
4. Strategy for "detoxification" of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2.
Brown ZZ; Müller MM; Jain SU; Allis CD; Lewis PW; Muir TW
J Am Chem Soc; 2014 Oct; 136(39):13498-501. PubMed ID: 25180930
[TBL] [Abstract][Full Text] [Related]
5. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for inactivation of PRC2 by G-quadruplex RNA.
Song J; Gooding AR; Hemphill WO; Love BD; Robertson A; Yao L; Zon LI; North TE; Kasinath V; Cech TR
Science; 2023 Sep; 381(6664):1331-1337. PubMed ID: 37733873
[TBL] [Abstract][Full Text] [Related]
7. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
[TBL] [Abstract][Full Text] [Related]
8. Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin.
Lee CH; Yu JR; Kumar S; Jin Y; LeRoy G; Bhanu N; Kaneko S; Garcia BA; Hamilton AD; Reinberg D
Mol Cell; 2018 May; 70(3):422-434.e6. PubMed ID: 29681499
[TBL] [Abstract][Full Text] [Related]
9. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.
Li L; Zhang H; Zhang M; Zhao M; Feng L; Luo X; Gao Z; Huang Y; Ardayfio O; Zhang JH; Lin Y; Fan H; Mi Y; Li G; Liu L; Feng L; Luo F; Teng L; Qi W; Ottl J; Lingel A; Bussiere DE; Yu Z; Atadja P; Lu C; Li E; Gu J; Zhao K
PLoS One; 2017; 12(1):e0169855. PubMed ID: 28072869
[TBL] [Abstract][Full Text] [Related]
11. Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors.
Chen F; Byrd AL; Liu J; Flight RM; DuCote TJ; Naughton KJ; Song X; Edgin AR; Lukyanchuk A; Dixon DT; Gosser CM; Esoe DP; Jayswal RD; Orkin SH; Moseley HNB; Wang C; Brainson CF
Nat Commun; 2023 Jan; 14(1):336. PubMed ID: 36670102
[TBL] [Abstract][Full Text] [Related]
12. Targeting EZH2 in cancer.
Kim KH; Roberts CW
Nat Med; 2016 Feb; 22(2):128-34. PubMed ID: 26845405
[TBL] [Abstract][Full Text] [Related]
13. Polycomb repressor complex 2 function in breast cancer (Review).
Martin CJ; Moorehead RA
Int J Oncol; 2020 Nov; 57(5):1085-1094. PubMed ID: 33491744
[TBL] [Abstract][Full Text] [Related]
14. An overview of the development of EED inhibitors to disable the PRC2 function.
Liu KL; Zhu K; Zhang H
RSC Med Chem; 2022 Jan; 13(1):39-53. PubMed ID: 35224495
[TBL] [Abstract][Full Text] [Related]
15. Advances in bi-directional relationships for EZH2 and oxidative stress.
Qin H; Liu C; Li C; Feng C; Bo Huang
Exp Cell Res; 2024 Jan; 434(1):113876. PubMed ID: 38070859
[TBL] [Abstract][Full Text] [Related]
16. Three additional patients with EED-associated overgrowth: potential mutation hotspots identified?
Spellicy CJ; Peng Y; Olewiler L; Cathey SS; Rogers RC; Bartholomew D; Johnson J; Alexov E; Lee JA; Friez MJ; Jones JR
J Hum Genet; 2019 Jun; 64(6):561-572. PubMed ID: 30858506
[TBL] [Abstract][Full Text] [Related]
17. PROTAC Linkerology Leads to an Optimized Bivalent Chemical Degrader of Polycomb Repressive Complex 2 (PRC2) Components.
Bashore FM; Foley CA; Ong HW; Rectenwald JM; Hanley RP; Norris-Drouin JL; Cholensky SH; Mills CA; Pearce KH; Herring LE; Kireev D; Frye SV; James LI
ACS Chem Biol; 2023 Mar; 18(3):494-507. PubMed ID: 36877831
[TBL] [Abstract][Full Text] [Related]
18. PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.
Patel AJ; Warda S; Maag JLV; Misra R; Miranda-Román MA; Pachai MR; Lee CJ; Li D; Wang N; Bayshtok G; Fishinevich E; Meng Y; Wong EWP; Yan J; Giff E; Pappalardi MB; McCabe MT; Fletcher JA; Rudin CM; Chandarlapaty S; Scandura JM; Koche RP; Glass JL; Antonescu CR; Zheng D; Chen Y; Chi P
Cancer Discov; 2022 Sep; 12(9):2120-2139. PubMed ID: 35789380
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic mechanisms of tumor resistance to immunotherapy.
Arenas-Ramirez N; Sahin D; Boyman O
Cell Mol Life Sci; 2018 Nov; 75(22):4163-4176. PubMed ID: 30140960
[TBL] [Abstract][Full Text] [Related]
20. Insight into the Inhibitory Mechanism of Embryonic Ectoderm Development Subunit by Triazolopyrimidine Derivatives as Inhibitors through Molecular Dynamics Simulation.
Ju J; Zhang H; Guan S; Liu C; Du J; Shen X; Wang S
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
